Publisher Correction: Feasibility of multiomics tumor profiling for guiding treatment of melanoma

In the version of the article initially published, the far-right column of the lower panel in Fig. 2c was missing and has now been added, as seen in Fig. 1, below. Additionally, the sentence “L.P. is a founder and shareholder of Apricot Therapeutics - a precision oncology spin-off from the University of Zurich - based on 4i drug response profiling” was missing from the Competing interests statement and has now been added. These corrections have been made to the HTML and PDF versions of the article.

Schlagwörter

Drug therapy, Erratum, Human, Male, Diagnosis

Fachgebiet (DDC)

610 - Medizin und Gesundheit

Projekt

Veranstaltung

Startdatum der Ausstellung

Enddatum der Ausstellung

Startdatum der Konferenz

Enddatum der Konferenz

Datum der letzten Prüfung

ISBN

ISSN

1078-8956
1546-170X

Sprache

Englisch

Während FHNW Zugehörigkeit erstellt

Ja

Zukunftsfelder FHNW

Publikationsstatus

Veröffentlicht

Begutachtung

Peer-Review der ganzen Publikation

Open Access-Status

Gold

Lizenz

Zitation

Miglino, N., Toussaint, N. C., Ring, A., Bonilla, X., Tusup, M., Gosztonyi, B., Mehra, T., Gut, G., Jacob, F., Chevrier, S., Lehmann, K.-V., Casanova, R., Jacobs, A., Sivapatham, S., Boos, L., Rahimzadeh, P., Schuerch, M., Sobottka, B., Chicherova, N., et al. (2025). Publisher Correction: Feasibility of multiomics tumor profiling for guiding treatment of melanoma. Nature Medicine, 31, 2817–2818. https://doi.org/10.1038/s41591-025-03904-3

Komplettanzeige